Safety and efficacy of palonosetron and aprepitant with dexamethasone for prevention of nausea and vomiting in patients with multiple myeloma undergoing autologous transplantation.

Trial Profile

Safety and efficacy of palonosetron and aprepitant with dexamethasone for prevention of nausea and vomiting in patients with multiple myeloma undergoing autologous transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone (Primary) ; Palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2017 New trial record
    • 01 Apr 2017 Results published in the International Journal of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top